Newtyn Management LLC bought a new stake in shares of Indivior PLC (NASDAQ:INDV – Free Report) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 1,305,795 shares of the company’s stock, valued at approximately $53,577,000. Indivior accounts for about 6.8% of Newtyn Management LLC’s investment portfolio, making the stock its 3rd largest position.
Several other hedge funds also recently added to or reduced their stakes in INDV. Caitong International Asset Management Co. Ltd raised its stake in shares of Indivior by 72.7% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,093 shares of the company’s stock valued at $39,000 after buying an additional 460 shares during the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al lifted its holdings in shares of Indivior by 3.4% in the 4th quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 21,200 shares of the company’s stock valued at $761,000 after buying an additional 700 shares during the period. Quarry LP purchased a new stake in shares of Indivior in the third quarter worth about $26,000. Rockefeller Capital Management L.P. boosted its stake in shares of Indivior by 512.4% in the fourth quarter. Rockefeller Capital Management L.P. now owns 1,286 shares of the company’s stock worth $46,000 after buying an additional 1,076 shares during the last quarter. Finally, GAMMA Investing LLC acquired a new stake in Indivior during the second quarter worth about $66,000. 60.33% of the stock is owned by hedge funds and other institutional investors.
Insider Buying and Selling
In related news, CAO Woodrow D. Anderson acquired 1,500 shares of the stock in a transaction on Thursday, August 27th. The shares were bought at an average price of $35.69 per share, with a total value of $53,535.00. Following the completion of the purchase, the chief accounting officer owned 27,638 shares of the company’s stock, valued at approximately $986,400.22. This represents a 5.74% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Ryan Preblick sold 36,000 shares of the business’s stock in a transaction dated Monday, June 8th. The shares were sold at an average price of $37.70, for a total transaction of $1,357,200.00. Following the transaction, the chief financial officer directly owned 284,751 shares in the company, valued at approximately $10,735,112.70. The trade was a 11.22% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.74% of the stock is currently owned by company insiders.
Analyst Upgrades and Downgrades
Check Out Our Latest Research Report on Indivior
Indivior Price Performance
INDV opened at $34.87 on Monday. The company has a market cap of $4.12 billion, a price-to-earnings ratio of 12.50 and a beta of 0.86. Indivior PLC has a 52-week low of $22.22 and a 52-week high of $42.81. The firm’s fifty day simple moving average is $39.33 and its two-hundred day simple moving average is $36.01.
Indivior (NASDAQ:INDV – Get Free Report) last posted its quarterly earnings data on Tuesday, June 30th. The company reported $5.75 earnings per share (EPS) for the quarter. The company had revenue of $343.00 million for the quarter. Indivior had a negative return on equity of 283.11% and a net margin of 26.65%. On average, research analysts forecast that Indivior PLC will post 3.66 EPS for the current year.
Indivior Profile
Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.
Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.
Featured Articles
- Five stocks we like better than Indivior
- Strike a Balance Between Growth and Stability With These 3 Names Ready to Rally
- Rubrik’s AI Security Bet Could Power the Next Leg Higher
- Apple’s Foldable iPhone Could Be a Catalyst, But Not a Cure-All
- Snowflake Is Up Nearly 50% in 2026—What Are Short Sellers Betting Against?
Want to see what other hedge funds are holding INDV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Indivior PLC (NASDAQ:INDV – Free Report).
Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with MarketBeat.com's FREE daily email newsletter.
